On November 25, 2024 Agendia, Inc., reported that new data on its early-stage breast cancer genomic tests and their ability to inform treatment selection decisions will be presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), taking place in San Antonio, TX, December 10th – 13th, 2024 (Press release, Agendia, NOV 25, 2024, View Source [SID1234648633]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presented data highlights Agendia’s continued focus on expanding clinical utility of the tests and optimizing breast cancer management throughout the patient’s treatment journey. These studies further enhance the robust body of clinical research supporting the clinical utility of Agendia’s MammaPrint and BluePrint in providing reliable guidance for therapeutic decisions in early-stage breast cancer.

Five Agendia abstracts have been accepted, including two poster spotlight presentations and one late-breaking poster. The following are details of the abstracts that have been accepted, which can also be found on the SABCS website here:

Poster Spotlight Presentations:

MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients with HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX.
Authors: O’Shaughnessy, J., et al.
Session: Poster Spotlight Session 4: Prediction of Chemotherapy Response
Date/Time: Wednesday, December 11 | 7:00 AM – 8:30 AM CST
Abstract #: 2091
Association of MammaPrint with Gene Expression Pathways Predictive of Resistance to Cyclin Dependent Kinase Inhibition
Authors: Brufsky, A., et al.
Session: Poster Spotlight Session 2: Personalizing CDK 4/6 Inhibitor Therapy for Patients with Metastatic Breast Cancer: Survival, QOL and Biomarkers
Date/Time: Thursday, December 12 | 7:00 AM – 8:30 AM CST
Abstract #: SESS-2068
Poster Presentations:

Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine – Biology is Still King
Authors: Rahman, R., et al.
Session: Poster Session 1
Date/Time: Wednesday, December 11 | 12:30 PM – 2 PM CST
Abstract #: 1879
FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer
Authors: Maganini, R.
Session: Poster Session 2
Date/Time: Wednesday, December 11 | 5:30 PM – 7:00 PM CST
Abstract #: 2160
Late-Breaking Poster:

Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early-Stage Breast Cancer Revealed by the FLEX Registry of Real-World Data
Authors: Brufsky, A., et al.
Session: Poster Session 2
Date/Time: Wednesday, December 11 | 5:30 PM – 7:00 PM CST
Abstract #: 3660
In addition, William Audeh, MD, MS, Chief Medical Officer of Agendia, will be presenting at Agendia’s Product Theater session, titled "How Can Genomic Information From A Single Core Biopsy Sample Inform Multiple Therapy Decisions For Early-Stage ER+ Breast Cancer?," demonstrating how MammaPrint and BluePrint can inform early-stage ER+ breast cancer treatment decisions. The educational session will take place on December 11th at 5:30 PM – 6:30 PM CST. Registration details can be found here.

More information about the full program can be found at the SABCS 2024 website.